Melanoma & Skin Cancer | Specialty

Managing Toxicity of Immunotherapy in Melanoma

February 24th 2015

Treatment Duration for PD-1 Inhibitors in Melanoma

February 24th 2015

Immunotherapy in BRAF Wild-Type Advanced Melanoma

February 24th 2015

Frontline Therapy for BRAF-Mutated Unresectable Melanoma

February 24th 2015

Treatment Approaches for Resectable Melanoma

February 24th 2015

Cobimetinib Receives Priority Review for Advanced Melanoma

February 19th 2015

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

FDA Schedules Advisory Meeting for T-VEC in Metastatic Melanoma

February 12th 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy talimogene laherparepvec as a treatment for patients with metastatic melanoma.

Novel Molecular Test Contributes to Definitive Diagnosis in Melanoma

February 12th 2015

The Myriad myPath Melanoma molecular diagnostic test was effective in helping practitioners differentiate between benign and malignant melanocytic lesions, according to results from a prospective study.

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12th 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

Dr. Jeffrey Weber on Ipilimumab for Melanoma

February 2nd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.

Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma

January 29th 2015

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, talks about the toxicity of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

PD-1 Inhibition: The Changing Treatment Paradigm for Melanoma

January 29th 2015

An increased understanding of tumor immunology has led to seven new melanoma drug approvals since 2011, including the recent approvals of the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma

January 27th 2015

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.

Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

January 13th 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Expert Discusses Integration of PD-1 Inhibitors Into Clinical Practice

January 13th 2015

To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.

Expanded RAS Mutation Testing in mCRC

January 1st 2015

2014 Year in Review

January 1st 2015

FDA Approves Nivolumab for Advanced Melanoma

December 22nd 2014

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

The Evolving Treatment Landscape in Advanced Melanoma

December 18th 2014

Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.

Rosenberg's Many Breakthroughs Fueled by Passion and Hard Work

November 21st 2014

Steven Rosenberg always knew that he wanted to become a physician scientist, and he quickly advanced to become the chief of surgery at the National Cancer Institute (NCI) at just 34 years of age.